Skip to content
BHP

Semaglutide

Ozempic · Wegovy · Rybelsus · NN9535 · NN9924 (oral)

Reviewed by the BestHealingPeptides Editorial Team ·

On this page

What is semaglutide, and is it a peptide?

Semaglutide is a peptide medicine: a linear chain of 31 amino acids with an attached fatty-acid chain, acting as a GLP-1 receptor agonist (a GLP-1 analogue with 94% sequence homology to human GLP-1). In the UK it is the active substance in the prescription only medicines Ozempic and Rybelsus (type 2 diabetes) and Wegovy (weight management, among other indications).

Sources: PubChem compound 56843331; Ozempic SmPC (emc)

Sourced facts at a glance

  • Structure: A polypeptide with a linear sequence of 31 amino acids joined by peptide linkages, also classed as a lipopeptide. Molecular formula C187H291N45O59; molecular weight 4114 g/mol. (PubChem compound 56843331)
  • Relationship to GLP-1: A GLP-1 analogue with 94% sequence homology to human GLP-1, produced in Saccharomyces cerevisiae cells by recombinant DNA technology; elimination half-life of approximately 1 week. (Ozempic SmPC (emc))
  • UK brands and licensed indications: Ozempic and Rybelsus are indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, for weight management in adults with a BMI of 30 kg/m2 or more, or 27 to under 30 kg/m2 with at least one weight-related comorbidity; in adolescents aged 12 and over with obesity and body weight above 60 kg; to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; and, with diet and exercise, for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (stages F2 to F3). Wegovy tablets are indicated, with a reduced-calorie diet and increased physical activity, for weight management in adults with a BMI of 30 kg/m2 or more, or 27 to under 30 kg/m2 with at least one weight-related comorbidity. All are listed as prescription only medicines. (Ozempic SmPC; Rybelsus SmPC; Wegovy SmPC; Wegovy tablets SmPC)
  • EU marketing authorisations (EMA): Ozempic issued 8 February 2018; Rybelsus issued 3 April 2020; Wegovy issued 6 January 2022. (EMA Ozempic EPAR; EMA Rybelsus EPAR; EMA Wegovy EPAR)
  • UK SmPC dates of first authorisation: Wegovy injection: 10 May 2022. Wegovy tablets: 11 June 2026. (Wegovy SmPC; Wegovy tablets SmPC)
  • US FDA original approvals: Ozempic 5 December 2017; Rybelsus 20 September 2019; Wegovy 4 June 2021. (Drugs@FDA Ozempic; Drugs@FDA Rybelsus; Drugs@FDA Wegovy)
  • Weight-management trial result (STEP 1): In 1,961 adults with overweight or obesity and without diabetes, mean body-weight change at week 68 was -14.9% with once-weekly subcutaneous semaglutide versus -2.4% with placebo, both plus lifestyle intervention. (Wilding et al., NEJM 2021 (PMID 33567185))

A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous injection and oral tablets). The most clinically significant GLP-1 receptor agonist of the late 2020s.

Mechanism of action

Yes — Ozempic is a peptide. Its active ingredient, semaglutide, is a synthetic analogue of the human gut hormone GLP-1 (glucagon-like peptide-1), sharing 94% sequence homology with native GLP-1, and it works by selectively binding to and activating the GLP-1 receptor — the same receptor targeted by the natural hormone (UK Summary of Product Characteristics; FDA prescribing information). The peptide backbone is produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology, then chemically modified at amino-acid position 8 to resist degradation by the DPP-4 enzyme and at lysine 26 with a C18 fatty-diacid chain that binds circulating albumin — extending the plasma half-life to roughly one week and enabling once-weekly subcutaneous dosing. Ozempic is MHRA-licensed in the UK for type-2 diabetes; the same molecule, at a higher dose, is licensed as Wegovy for weight management.

Semaglutide is a 31-amino-acid synthetic peptide structurally derived from native human GLP-1 with two engineered modifications that confer dramatic plasma half-life extension and protease resistance. The first modification is substitution of native alanine at position 8 with α-aminoisobutyric acid (Aib), an unnatural amino acid that blocks dipeptidyl peptidase-4 (DPP-4)-mediated cleavage of the N-terminal His-Ala bond — the principal degradation pathway of native GLP-1 (plasma half-life ~2 minutes). The second modification is covalent attachment of a C18 fatty diacid moiety to the ε-amino group of lysine 26 via a γ-glutamic acid and two short polyethylene glycol-like linkers (2xOEG). The fatty diacid chain binds non-covalently but with very high affinity to circulating serum albumin (~67 kDa), shielding the peptide from renal filtration and protease degradation and producing the ~7-day plasma half-life that supports once-weekly subcutaneous dosing.

Mechanistically, semaglutide functions as a full GLP-1 receptor agonist with binding affinity comparable to native GLP-1. The GLP-1R is a 463-residue class B G-protein-coupled receptor expressed prominently on pancreatic β-cells (the principal therapeutic target), pancreatic α-cells, intestinal mucosa, central neurons (hypothalamic arcuate nucleus, area postrema), peripheral vagal neurons, vascular smooth muscle, and other tissues. Receptor activation triggers Gαs/adenylate cyclase signalling, raising intracellular cAMP and activating both protein kinase A (PKA) and the Epac2 guanine nucleotide exchange factor.

The principal therapeutic effects emerge from receptor activation in distinct tissues. β-cell GLP-1R activation potentiates glucose-stimulated insulin secretion in a strictly glucose-dependent manner — at low glucose concentrations the insulinotropic signal is minimal, which provides the favourable hypoglycaemia profile that distinguishes incretin-based therapy from sulphonylureas. α-cell GLP-1R activation suppresses glucagon secretion, providing a complementary glucose-lowering mechanism. Central GLP-1R activation in the hypothalamic arcuate nucleus and brainstem area postrema drives appetite suppression, early satiety, and reduced food intake — the principal mechanism behind the dramatic weight-loss efficacy seen at higher dose tiers (Wegovy). Peripheral effects include slowed gastric emptying (which flattens the postprandial glucose excursion), modest blood pressure reduction, and emerging neuroprotective effects.

The oral semaglutide formulations (Rybelsus and Wegovy tablets) address the standard gastric peptide-degradation problem through co-formulation with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), an absorption enhancer that temporarily raises gastric pH and protects semaglutide from peptidase degradation during a narrow gastric absorption window. Oral bioavailability is materially lower than subcutaneous (~1% versus near-complete), but the SNAC platform enables daily oral dosing as an alternative to weekly injection. Per section 5.2 of the Rybelsus SmPC, two formulations of the tablets exist, 1.5 mg, 4 mg and 9 mg (round tablets) and 3 mg, 7 mg and 14 mg (oval tablets); bioequivalent doses of the two formulations are given in the SmPC, and both have live UK SmPCs on the emc. The phase 3a PIONEER trials used the 3, 7 and 14 mg tablets.

Downstream metabolic effects of sustained GLP-1R activation produce the characteristic semaglutide phenotype: 1-2% absolute HbA1c reduction in type-2 diabetes, 6-15% body weight reduction (depending on dose and duration), favourable lipid changes, modest blood pressure reduction, and cardiovascular event reduction documented in dedicated outcome trials (SUSTAIN-6, PIONEER, STEP, SELECT). The strictly glucose-dependent insulinotropic profile means severe hypoglycaemia is rare in monotherapy use; risk rises with concurrent sulphonylurea or insulin therapy.

Semaglutide 2.4 mg subcutaneous weekly produces 14.9% mean body weight loss over 68 weeks in non-diabetic adults with obesity (STEP 1, Wilding et al., NEJM 2021) — the largest pharmacological weight-loss effect documented in a peer-reviewed trial at the time of publication, transforming the regulatory and commercial landscape of obesity therapeutics.

— Notable finding

Development history

Semaglutide was developed by Novo Nordisk through systematic medicinal chemistry building on the company's experience with liraglutide, the first commercially successful long-acting GLP-1R agonist (FDA-approved 2010, MHRA-licensed shortly after). The development goal was once-weekly rather than once-daily dosing through extended fatty-acid-acylation chemistry, which became the principal differentiator of semaglutide over liraglutide and exenatide. Phase II development confirmed the once-weekly dosing pharmacology; Phase III SUSTAIN programme (multiple trials across type-2 diabetes settings) established efficacy and safety, supporting first FDA approval (Ozempic, December 2017) and MHRA marketing authorisation shortly after.

The SUSTAIN-6 cardiovascular outcome trial (Marso et al., NEJM 2016) — published before regulatory approval — established MACE reduction with semaglutide in type-2 diabetes patients with established cardiovascular disease, paralleling the LEADER trial results for liraglutide. Cardiovascular benefit at the class level (GLP-1R agonists) transformed the regulatory and reimbursement landscape, supporting broader use beyond pure glycaemic control.

The weight-management indication emerged from observation that the higher dose tiers used in some Phase III trials produced substantial weight loss beyond the glycaemic control. The STEP programme (multiple Phase III trials, 2018-2021) tested semaglutide 2.4 mg subcutaneous weekly in obesity without diabetes, demonstrating ~15% mean body weight reduction over 68 weeks — substantially larger than any prior pharmacological weight-loss intervention. Wegovy received FDA approval in June 2021 and MHRA marketing authorisation in 2022, generating the explosive 'GLP-1 weight loss' commercial and cultural phenomenon of 2023-2025. UK supply constraints were severe through 2023-2024, partially resolved by 2025-2026.

The oral semaglutide formulation (Rybelsus) received FDA approval in September 2019 and MHRA marketing authorisation in 2020 as the first orally bioavailable GLP-1R agonist, enabled by the SNAC absorption-enhancer platform licensed from Emisphere Technologies. The SELECT cardiovascular outcome trial (2023) extended cardiovascular benefit to non-diabetic obese subjects, further broadening the population eligible for chronic GLP-1R agonist therapy.

In the UK in 2025-2026, semaglutide is widely prescribed for type-2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), with NICE technology appraisal guidance supporting NHS prescription within specified eligibility criteria. The compound has materially altered the standard-of-care landscape for both conditions.

Licensed dose regimens

The regimens below are summarised from the UK Summaries of Product Characteristics. They are not a dosing recommendation; follow your prescriber.

Licensed Semaglutide dose regimens
IndicationRouteRegimenNote
Type-2 diabetes (Ozempic, MHRA-licensed)Subcutaneous, once weeklyStart 0.25 mg/week × 4 weeks; increase to 0.5 mg/week; after at least 4 weeks the dose can be increased to 1 mg/week, and after at least 4 weeks on 1 mg to 2 mg/weekOzempic SmPC section 4.2. 0.25 mg is not a maintenance dose; weekly doses above 2 mg are not recommended. NICE NG28 recommends offering subcutaneous semaglutide, up to 1 mg once a week, to adults with type 2 diabetes and atherosclerotic cardiovascular disease.
Chronic weight management (Wegovy, MHRA-licensed)Subcutaneous, once weeklyStart 0.25 mg/week × 4 weeks; escalate over 16 weeks (0.5, 1, 1.7 mg) to 2.4 mg/week maintenance; if needed in adults with obesity, 7.2 mg/week after a minimum of 4 weeks on 2.4 mgWegovy injection SmPC section 4.2: the dose should be escalated over a 16-week period to reduce the likelihood of gastrointestinal symptoms. 2.4 mg is the dose studied in STEP 1 (~15% mean weight loss).
Chronic weight management (Wegovy tablets, MHRA-licensed)Oral tablet, once daily on empty stomachStart 1.5 mg/day × 1 month; then 4 mg, 9 mg and 25 mg/day with a minimum of 1 month at each dose; 25 mg/day is the maintenance dose and the maximumWegovy tablets SmPC section 4.2: empty stomach after at least 8 hours fasting, swallowed whole with a sip of water (up to 120 mL), then wait at least 30 minutes before eating, drinking or taking other oral medicines.
Type-2 diabetes (Rybelsus, MHRA-licensed)Oral tablet, once daily on empty stomach1.5 mg/day × 1 month, then 4 mg/day; after at least 1 month on 4 mg, 9 mg/day if needed (maximum 9 mg). The 3, 7 and 14 mg oval-tablet formulation follows the same steps (3 mg × 1 month, then 7 mg, then 14 mg; maximum 14 mg)Rybelsus SmPC: two bioequivalent formulations are authorised, 1.5/4/9 mg (round) and 3/7/14 mg (oval) (section 5.2). Section 4.2: take on an empty stomach after a fasting period of at least 8 hours, swallow whole with a sip of water (up to 120 mL), then wait at least 30 minutes before eating, drinking or taking other oral medicines; waiting less than 30 minutes decreases absorption.
Licensed regimens summarised from the UK Summaries of Product Characteristics. Not a dosing recommendation; follow your prescriber.

Reconstitution & storage

Summarised studies

Summarised research studies
YearModelOutcomeCitationSource
2016Type-2 diabetes adults with elevated cardiovascular risk, RCTMACE reduction HR 0.74; significant nonfatal stroke reduction; transient eye-complication signalMarso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834-1844PMID 27633186
2021Non-diabetic adults with obesity, RCT14.9% mean weight loss versus 2.4% placebo; favourable cardiometabolic profileWilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002PMID 33567185
2023Non-diabetic adults with obesity and CVD, RCT20% MACE reduction; cardiovascular mortality reductionLincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023;389(24):2221-2232PMID 37952131
2019Type-2 diabetes adults with elevated cardiovascular risk, RCTMACE non-inferiority; trend toward benefitHusain M, Birkenfeld AL, Donsmark M, et al. N Engl J Med. 2019;381(9):841-851PMID 31185157
2024Network meta-analysesEstablished semaglutide as preferred GLP-1R agonist of the late-2020s era for combined glycaemia and weight outcomesMultiple network meta-analyses and indirect comparisons across the SUSTAIN, AWARD, LEAD, and DURATION programmes—

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)

Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834-1844 · 2016 · PMID 27633186

Landmark cardiovascular outcomes trial demonstrating MACE reduction (HR 0.74) with semaglutide 0.5 or 1.0 mg subcutaneous weekly versus placebo in 3,297 type-2 diabetes patients with established cardiovascular disease or cardiovascular risk factors over 104 weeks. Established cardiovascular benefit beyond glycaemic control.

PubMed

Once-weekly semaglutide in adults with overweight or obesity (STEP 1)

Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002 · 2021 · PMID 33567185

Pivotal weight-management trial of semaglutide 2.4 mg subcutaneous weekly versus placebo in 1,961 non-diabetic adults with BMI ≥30 (or ≥27 with comorbidity) over 68 weeks. Mean weight loss 14.9% versus 2.4% placebo — the largest pharmacological weight-loss effect documented in a peer-reviewed trial at the time.

PubMed

Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023;389(24):2221-2232 · 2023 · PMID 37952131

Cardiovascular outcomes trial of semaglutide 2.4 mg subcutaneous weekly in 17,604 non-diabetic adults with BMI ≥27 and established cardiovascular disease. MACE reduction 20% (HR 0.80) over mean 39.8 months follow-up, establishing cardiovascular benefit of semaglutide in obesity without diabetes.

PubMed

Oral semaglutide and cardiovascular outcomes in type 2 diabetes (PIONEER 6)

Husain M, Birkenfeld AL, Donsmark M, et al. N Engl J Med. 2019;381(9):841-851 · 2019 · PMID 31185157

Cardiovascular outcomes trial of oral semaglutide 14 mg daily versus placebo in 3,183 type-2 diabetes patients with cardiovascular risk. Non-inferiority for MACE established with point estimate suggesting benefit (HR 0.79). The 14 mg oval tablet used in the trial is bioequivalent to the 9 mg round tablet (Rybelsus SmPC section 5.2).

PubMed

Comparative efficacy and safety of GLP-1 receptor agonists in adults with type 2 diabetes

Multiple network meta-analyses and indirect comparisons across the SUSTAIN, AWARD, LEAD, and DURATION programmes · 2024

Comparative effectiveness analyses positioning semaglutide as more efficacious than liraglutide, exenatide, lixisenatide, and dulaglutide for glycaemic and weight outcomes in type-2 diabetes, with tirzepatide subsequently surpassing semaglutide on weight-loss endpoints.

Safety profile

Semaglutide has the largest published clinical-trial safety dataset of any peptide drug, accumulated through the SUSTAIN, PIONEER, STEP, SELECT, and post-marketing surveillance programmes spanning over 50,000 trial participants and millions of post-marketing exposures. The principal documented adverse events are gastrointestinal: nausea (15-44% depending on dose), vomiting (5-25%), diarrhoea (10-30%), and constipation (15-25%). These are dose-dependent, most prominent during dose escalation, and generally mild-to-moderate; they account for the majority of treatment discontinuations. Dose-titration protocols (starting at 0.25 mg subcutaneous weekly, escalating to therapeutic doses over 16+ weeks) substantially mitigate the GI symptom burden.

The glucose-dependent insulinotropic mechanism produces a favourable hypoglycaemia profile in monotherapy. Severe hypoglycaemia is rare when semaglutide is used alone or with metformin; risk rises materially with concurrent sulphonylurea or insulin therapy, where dose reductions of the concurrent agents are recommended.

Less common but clinically significant adverse events documented in the published trials include acute pancreatitis (uncommon, with absolute rates of 0.3-0.5% but elevated relative to placebo in some analyses), acute biliary disease (cholecystitis and cholelithiasis, related to rapid weight loss and GLP-1 effects on biliary motility), modest heart rate elevation (~2-5 bpm), injection-site reactions for the subcutaneous formulations, and rare reports of diabetic retinopathy progression in patients with pre-existing severe retinopathy.

The theoretical thyroid C-cell carcinoma concern carried forward from earlier GLP-1R agonists (liraglutide, exenatide) — based on rodent thyroid C-cell hyperplasia in chronic toxicity studies — is reflected in the FDA boxed warning. The UK Summaries of Product Characteristics (Ozempic, Wegovy, Rybelsus) list hypersensitivity as the only contraindication in section 4.3; the rodent thyroid C-cell tumours are described as a GLP-1 receptor agonist class effect in section 5.3, which says their relevance for humans is considered to be low, but cannot be completely excluded. Large epidemiological analyses have not confirmed an increased medullary thyroid carcinoma risk in GLP-1R-agonist-treated patients.

The SELECT and STEP programmes documented favourable cardiovascular and renal safety profiles, with the SUSTAIN-6 and SELECT trials demonstrating MACE reduction in cardiovascular-risk populations. Mood and suicidality concerns raised in 2023-2024 by isolated case reports have been examined in formal regulatory reviews (FDA, EMA, MHRA) which concluded that the available evidence does not establish a causal association between semaglutide therapy and suicidality, though monitoring continues.

Anti-semaglutide antibodies develop in a small proportion of treated patients but are generally non-neutralising and have not produced documented loss of efficacy.

Reported contraindications & cautions

  • Hypersensitivity to semaglutide or any excipient (the only contraindication listed in SmPC section 4.3)
  • Pregnancy: should not be used; discontinue if pregnancy occurs, and at least 2 months before a planned pregnancy because of the long half-life (SmPC section 4.6)
  • Breast-feeding: should not be used (SmPC section 4.6)
  • Not a substitute for insulin (Ozempic and Wegovy SmPCs, section 4.4); the Ozempic and Rybelsus SmPCs add that semaglutide should not be used in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
  • Gastroparesis: more serious or severe gastrointestinal adverse events may occur; use with caution, and not recommended if severe (SmPC section 4.4)
  • History of pancreatitis: not studied, use with caution; if acute pancreatitis is suspected stop treatment, and do not restart if confirmed (SmPC section 4.4)
  • Rodent thyroid C-cell tumours are a GLP-1 receptor agonist class effect (SmPC section 5.3) and the FDA label carries a boxed warning; history of medullary thyroid carcinoma or MEN-2 is not a listed UK SmPC contraindication, so discuss it with the prescriber

Known interactions (product label)

  • Sulphonylureas and insulin: increased hypoglycaemia risk; dose reduction of concurrent agent recommended.
  • Warfarin and other oral medications: slowed gastric emptying may affect absorption kinetics; monitor INR and other drug-effect markers.
  • Oral semaglutide (Rybelsus, Wegovy tablets): must be taken 30 minutes before food, drink, or other oral medications to enable SNAC-mediated absorption; failure to follow timing reduces bioavailability.
  • Levothyroxine and other narrow-therapeutic-index oral drugs: gastric emptying effects may modestly alter absorption.
  • No CYP-mediated drug-drug interactions are clinically significant — semaglutide is metabolised by proteolytic peptidases rather than CYP enzymes.

UK regulatory status

Semaglutide is fully MHRA-licensed in the United Kingdom across several products and indications. Ozempic (semaglutide 0.5, 1 and 2 mg subcutaneous weekly) is licensed for type-2 diabetes mellitus in adults. Wegovy injection (semaglutide 2.4 mg subcutaneous weekly, reached by escalating the dose over 16 weeks; 7.2 mg weekly can be used after at least 4 weeks on 2.4 mg for weight management in adults with obesity) and Wegovy tablets (semaglutide 1.5, 4, 9 and 25 mg once daily) are licensed for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity. Rybelsus tablets are licensed for type-2 diabetes mellitus in adults; two bioequivalent formulations are authorised, 1.5, 4 and 9 mg (round tablets) and 3, 7 and 14 mg (oval tablets).

NHS prescription of Wegovy for obesity is supported by NICE technology appraisal guidance TA875 (semaglutide for managing overweight and obesity) within specified eligibility criteria, while for type-2 diabetes NICE guideline NG28 (type 2 diabetes in adults: management, updated February 2026) recommends offering subcutaneous semaglutide (Ozempic), up to 1 mg once a week, to adults with type 2 diabetes and atherosclerotic cardiovascular disease (recommendations 1.15.1, 1.15.2 and 1.27.1); for some other groups, such as adults with early-onset type 2 diabetes or with obesity who need further medicines, it recommends considering a GLP-1 receptor agonist or tirzepatide. NHS supply of Wegovy is restricted to specialist obesity services or under shared-care arrangements; private prescription is also available.

Semaglutide is a Prescription Only Medicine (POM) under the Human Medicines Regulations 2012. Supply or possession for human use outside a valid prescription is regulated. There is no controlled-drug classification under the Misuse of Drugs Act 1971. Unauthorised online supply of unlicensed or counterfeit semaglutide has been a recurring MHRA enforcement concern, particularly during the 2023-2024 supply shortages; the MHRA has published multiple warnings about counterfeit Ozempic and Wegovy entering the UK supply chain through unauthorised channels.

Semaglutide is not on the WADA Prohibited List as of 2026. Recreational athletic use raises distinct ethical and safety considerations but is not currently a doping violation.

Frequently asked questions

What is a semaglutide peptide, and how many amino acids does it contain?
Semaglutide is a peptide drug built on a linear sequence of 31 amino acids joined by peptide linkages, with an attached fatty-acid chain (PubChem classes it as both a polypeptide and a lipopeptide). Its molecular formula is C187H291N45O59 and its molecular weight is about 4114 g/mol. It acts as a GLP-1 receptor agonist: the UK Ozempic Summary of Product Characteristics describes it as a GLP-1 analogue with 94% sequence homology to human GLP-1, produced in Saccharomyces cerevisiae cells by recombinant DNA technology. Sources: PubChem compound 56843331; Ozempic SmPC on the emc.
What are the key facts about semaglutide?
Semaglutide is a peptide medicine: a linear chain of 31 amino acids with an attached fatty-acid chain, acting as a GLP-1 receptor agonist (a GLP-1 analogue with 94% sequence homology to human GLP-1). Its molecular formula is C187H291N45O59, its molecular weight is about 4114 g/mol and its elimination half-life is approximately 1 week (UK SmPC section 5.2). In the UK it is the active substance in the prescription only medicines Ozempic and Rybelsus (type 2 diabetes) and Wegovy (weight management, among other indications). In the STEP 1 trial of 1,961 adults with overweight or obesity and without diabetes, mean body-weight change at week 68 was -14.9% with once-weekly subcutaneous semaglutide 2.4 mg versus -2.4% with placebo, both plus lifestyle intervention. Sources: PubChem compound 56843331; Ozempic SmPC on the emc; Wilding et al., NEJM 2021 (PMID 33567185).
Are semaglutide peptides sold as research chemicals the same as Ozempic or Wegovy?
No. Semaglutide is a licensed prescription only medicine in the UK (Ozempic, Wegovy and Rybelsus are listed as prescription only medicines in their UK Summaries of Product Characteristics on the emc), not an unlicensed research chemical. The research-chemical-market supply of bulk lyophilised semaglutide for research-only use is a separate channel and is not the licensed product; any clinical use of semaglutide should use MHRA-licensed product through prescription.
Is Ozempic a peptide?
Yes. Ozempic's active ingredient is semaglutide, a synthetic peptide analogue of human GLP-1 (glucagon-like peptide-1) with 94% sequence homology to the native hormone. Its peptide backbone is produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology and then chemically modified for a long plasma half-life, before being formulated as a ready-to-use subcutaneous injection (semaglutide is also available as oral tablets, Rybelsus and Wegovy tablets) — Ozempic is a peptide medicine, not a small-molecule drug.
What is semaglutide made of?
Semaglutide's peptide backbone is produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology, then chemically modified at two points: amino-acid position 8 is altered to resist degradation by the DPP-4 enzyme, and lysine 26 carries a C18 fatty-diacid chain, attached via a hydrophilic spacer, that binds circulating albumin and extends the plasma half-life to around one week. A minor modification at position 34 ensures only one fatty-diacid chain attaches per molecule. The molecular formula is C187H291N45O59 (molecular weight 4,113.58 g/mol).
How is Ozempic different from natural GLP-1?
Semaglutide shares 94% of its amino-acid sequence with native human GLP-1, but two engineered modifications change its behaviour: a substitution at position 8 blocks the DPP-4 enzyme that rapidly clears the natural hormone, and a fatty-diacid chain attached at lysine 26 binds circulating albumin, shielding the peptide from clearance. Together these extend semaglutide's plasma half-life to around one week — which is why Ozempic is dosed once weekly by subcutaneous injection, whereas native GLP-1 is degraded within minutes.
What is the difference between Ozempic, Wegovy, and Rybelsus?
All three are semaglutide. Ozempic (0.5, 1 or 2 mg subcutaneous weekly) is licensed for type-2 diabetes. Wegovy (2.4 mg subcutaneous weekly, with 7.2 mg available after at least 4 weeks on 2.4 mg in adults with obesity; also available as once-daily tablets) is licensed for weight management at a higher dose. Rybelsus (oral daily; 1.5, 4 and 9 mg or 3, 7 and 14 mg tablets, two bioequivalent formulations) is an oral formulation co-formulated with the SNAC absorption enhancer, licensed for type-2 diabetes (Wegovy tablets are the oral formulation licensed for weight management). The active molecule is identical; the products differ in dose, formulation, and licensed indication.
Is semaglutide available on the NHS?
Yes — for type-2 diabetes, NICE guideline NG28 recommends offering subcutaneous semaglutide (Ozempic), up to 1 mg once a week, to adults with atherosclerotic cardiovascular disease. Wegovy NHS supply is restricted to specialist obesity services or under shared-care arrangements under NICE TA875 criteria (BMI ≥35 with comorbidity or BMI ≥30 in some contexts). Supply constraints during 2023-2024 affected NHS access and partially resolved by 2025-2026. Private prescription is available for all three.
Why does semaglutide cause weight loss?
GLP-1 receptor activation in the central nervous system (hypothalamic arcuate nucleus, area postrema) drives appetite suppression, early satiety, and reduced food intake. Peripheral effects include slowed gastric emptying, which flattens postprandial glucose excursions and reinforces satiety. The combined central and peripheral effects produce mean 14.9% body weight reduction over 68 weeks at the Wegovy dose (STEP 1 trial).
Does semaglutide cause hypoglycaemia?
Severe hypoglycaemia is rare with semaglutide monotherapy because the insulinotropic effect is strictly glucose-dependent — at low glucose concentrations the cAMP-driven insulin secretion signal is minimal. Risk rises materially when semaglutide is combined with sulphonylureas or insulin; dose reductions of the concurrent agents are recommended. This favourable hypoglycaemia profile distinguishes GLP-1R agonists from sulphonylureas.
What are the common side effects?
The principal adverse events are gastrointestinal: nausea (15-44%), vomiting (5-25%), diarrhoea (10-30%), and constipation (15-25%). These are dose-dependent, most prominent during dose escalation, and generally mild-to-moderate. Dose-titration over 16+ weeks substantially mitigates the GI symptom burden. Less common: acute pancreatitis (uncommon), acute biliary disease (related to rapid weight loss), modest heart rate elevation, and rare diabetic retinopathy progression in pre-existing severe retinopathy.
Is semaglutide prohibited in sport?
No — semaglutide is not on the WADA Prohibited List, and nor is the licensed GLP-1R agonist tirzepatide; unapproved investigational GLP-1-pathway drugs may fall under WADA's S0 category (non-approved substances). Recreational athletic use raises distinct ethical and safety considerations but is not a doping violation as of 2026. This contrasts with growth hormone-axis peptides (CJC-1295, sermorelin, ipamorelin) which are all WADA S2 prohibited.
What is the thyroid cancer warning?
Chronic toxicity studies in rodents (mice and rats) showed thyroid C-cell tumours with GLP-1R agonist exposure, described in section 5.3 of the UK Summaries of Product Characteristics as a class effect whose relevance for humans is considered to be low, but cannot be completely excluded. The FDA label carries a boxed warning; the UK SmPCs for Ozempic, Wegovy and Rybelsus list hypersensitivity as the only contraindication (section 4.3). Large epidemiological analyses have not confirmed an increased risk in treated patients. Anyone with a personal or family history of medullary thyroid carcinoma should discuss this with their prescriber.
When were Ozempic, Wegovy and Rybelsus approved?
European Medicines Agency (EPAR pages): Ozempic marketing authorisation issued 8 February 2018, Rybelsus 3 April 2020 and Wegovy 6 January 2022. UK Summaries of Product Characteristics (emc): the Wegovy injection SmPC gives a date of first authorisation of 10 May 2022, and the Wegovy tablets SmPC gives 11 June 2026. US FDA (Drugs@FDA original approvals): Ozempic 5 December 2017, Rybelsus 20 September 2019 and Wegovy 4 June 2021. Ozempic and Rybelsus are indicated for adults with insufficiently controlled type 2 diabetes; Wegovy is indicated for weight management in adults with a BMI of 30 kg/m2 or more, or 27 to under 30 kg/m2 with at least one weight-related comorbidity, and the Wegovy injection SmPC also lists adolescent weight management, cardiovascular risk reduction and MASH.
Is semaglutide a prescription-only medicine in the UK?
Yes. The UK Summaries of Product Characteristics for Ozempic, Wegovy and Rybelsus on the emc list each as a prescription only medicine, licensed for a specific indication (type 2 diabetes for Ozempic and Rybelsus; weight management among the indications for Wegovy).

References

  1. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016;375(19):1834-1844 (2016). PMID 27633186
  2. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002 (2021). PMID 33567185
  3. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. N Engl J Med. 2023;389(24):2221-2232 (2023). PMID 37952131
  4. Oral semaglutide and cardiovascular outcomes in type 2 diabetes (PIONEER 6). Husain M, Birkenfeld AL, Donsmark M, et al. N Engl J Med. 2019;381(9):841-851 (2019). PMID 31185157
  5. Comparative efficacy and safety of GLP-1 receptor agonists in adults with type 2 diabetes. Multiple network meta-analyses and indirect comparisons across the SUSTAIN, AWARD, LEAD, and DURATION programmes (2024).
  6. MHRA SmPC: Ozempic (semaglutide) — type 2 diabetes
  7. MHRA SmPC: Wegovy (semaglutide) — weight management
  8. MHRA SmPC: Rybelsus (oral semaglutide)
  9. FDA prescribing information (DailyMed): Ozempic (semaglutide) injection — Description & Mechanism of Action
  10. NICE TA875 — Wegovy for managing overweight and obesity
  11. NICE NG28 — Type 2 diabetes in adults: management
  12. PubChem — Semaglutide (CID 56843331)
  13. EMA EPAR — Ozempic
  14. EMA EPAR — Wegovy
  15. EMA EPAR — Rybelsus
  16. Drugs@FDA — Ozempic (NDA 209637)
  17. Drugs@FDA — Rybelsus (NDA 213051)
  18. Drugs@FDA — Wegovy (NDA 215256)
  19. Marso et al. 2016 — SUSTAIN-6 (PMID 27633186)
  20. Wilding et al. 2021 — STEP 1 (PMID 33567185)
  21. Lincoff et al. 2023 — SELECT (PMID 37952131)

Appears in research stacks

Side-by-side comparisons

Cited in research summaries

Related peptides